Literature DB >> 21755301

[Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. Results of a survey of patients, primary care physicians and rheumatologists].

I Heberlein1, W Demary, H Bloching, J Braun, F Buttgereit, R Dreher, C Kuhn, U Lange, A Zink, H Zeidler, H Häntzschel, H Raspe.   

Abstract

In a cross-sectional study the prevalence of osteoporosis and osteopenia in patients with rheumatoid arthritis (ORA study) was investigated. Additionally, patients, their family doctors and rheumatologists were surveyed on their awareness of osteoporosis in RA, prevention, diagnosis, treatment and use of guidelines.In the years 2005 and 2006 a total of 532 patients with RA (98 men, 434 women) aged 23-87 years were consecutively recruited from 9 German centers for rheumatology. Clinical examination included a detailed documentation of osteoporosis medication. Dual-energy X-ray absorptiometry (DXA) was used to measure bone mineral density (BMD) at the lumbar spine and neck of the femur. Questionnaires on osteoporosis were sent to 119 family doctors (87 men, 32 women) and 44 rheumatologists (30 men, 14 women).The survey showed that rheumatologists had a higher awareness of osteoporosis in RA and compared to family doctors they estimated a higher frequency and tested RA patients more often for osteoporosis. In line with osteoporosis guidelines rheumatologists and family doctors saw an indication for densitometry in RA patients on steroid therapy and/or low intensity trauma fractures. In contrast to the 2006 recommendations of osteoporosis guidelines 50% of family doctors and rheumatologists preferred bisphosphonate off-label-therapy for premeopausal women with RA and comorbid glucocorticoid-induced osteoporosis. On the other hand 50% of premenopausal RA patients with osteoporosis did not receive any osteoporosis medication.The survey revealed a high degree of guideline compliance in diagnosing osteoporosis in RA but deficits were observed in the administration of osteoporosis medication, especially in premenopausal women.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21755301     DOI: 10.1007/s00393-011-0821-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  11 in total

1.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.

Authors:  L Sinigaglia; A Nervetti; Q Mela; G Bianchi; A Del Puente; O Di Munno; B Frediani; F Cantatore; R Pellerito; S Bartolone; G La Montagna; S Adami
Journal:  J Rheumatol       Date:  2000-11       Impact factor: 4.666

Review 2.  Glucocorticoid-induced osteoporosis.

Authors:  Kenneth G Saag
Journal:  Endocrinol Metab Clin North Am       Date:  2003-03       Impact factor: 4.741

Review 3.  Bone mass measurement and bone metabolism in rheumatoid arthritis: a review.

Authors:  A A Deodhar; A D Woolf
Journal:  Br J Rheumatol       Date:  1996-04

4.  Body composition in rheumatoid arthritis.

Authors:  R Westhovens; J Nijs; V Taelman; J Dequeker
Journal:  Br J Rheumatol       Date:  1997-04

5.  [Cooperation between primary care physicians and rheumatologists in Lower Saxony. Results of a survey of primary care physicians].

Authors:  J L Hülsemann; S Mattussek; S Zeh; H Zeidler
Journal:  Z Rheumatol       Date:  2007-03       Impact factor: 1.372

6.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

7.  Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis.

Authors:  H Forsblad D'Elia; A Larsen; E Waltbrand; G Kvist; D Mellström; T Saxne; C Ohlsson; E Nordborg; H Carlsten
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

8.  Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

Authors:  J D Adachi; W G Bensen; J Brown; D Hanley; A Hodsman; R Josse; D L Kendler; B Lentle; W Olszynski; L G Ste-Marie; A Tenenhouse; A A Chines
Journal:  N Engl J Med       Date:  1997-08-07       Impact factor: 91.245

9.  Undertreatment of osteoporosis in men with hip fracture.

Authors:  Gary M Kiebzak; Garth A Beinart; Karen Perser; Catherine G Ambrose; Sherwin J Siff; Michael H Heggeness
Journal:  Arch Intern Med       Date:  2002-10-28

10.  Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis.

Authors:  N F Peel; D J Moore; N A Barrington; D E Bax; R Eastell
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

View more
  3 in total

1.  Guidance for the diagnosis, prevention and therapy of osteoporosis in Italy.

Authors:  Luisella Cianferotti; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

2.  Pattern of drugs use and association with anti-mutated citrullinated vimentin antibody in rheumatoid arthritis.

Authors:  Mohammad-Ayman A Safi; Omar A Fathaldin
Journal:  Saudi Med J       Date:  2015-03       Impact factor: 1.484

3.  Comorbidity profile among patients with rheumatoid arthritis and the impact on prescriptions trend.

Authors:  J Al-Bishri; Sm Attar; Nawal Bassuni; Yasser Al-Nofaiey; Hamed Qutbuddeen; Salma Al-Harthi; Sarah Subahi
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2013-04-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.